Efficacy News and Research

RSS

Positive results from Santarus and Pharming’s RUCONEST Phase III trial on HAE

Santarus, Inc. and Pharming Group NV today announced that their pivotal Phase III clinical study to evaluate the safety and efficacy of the investigational drug RUCONEST (recombinant human C1 esterase inhibitor) 50 U/kg for the treatment of acute attacks of angioedema in patients with Hereditary Angioedema (HAE) met the primary endpoint of time to beginning of symptom relief.

7 Nov 2012

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Taiho Pharmaceutical Co., Ltd., the developer of the first orally available fluorouracil (FU) Chemotherapeutic treatment (TS-1/S-1), is presenting early stage data for eight novel oncology compounds, including potential first-in-class therapies.

7 Nov 2012

Lexicon announces data from LX4211 Phase 2b trial on type 2 diabetes

Lexicon Pharmaceuticals, Inc. announced that data from the Phase 2b clinical trial of LX4211 are being presented today as a Clinical Sciences Special Report in the Emerging Therapeutics for Diabetes and Dyslipidemia section of the American Heart Association (AHA) Scientific Sessions Conference held in Los Angeles, California.

7 Nov 2012

Positive results from BioCardia's Helical Infusion System Phase 1/2 trial on ischemic cardiomyopathy

BioCardia, Inc., focused on regenerative biologic therapies for cardiovascular disease, today announced positive results from a Phase 1/2 heart failure trial using the Company's Helical Infusion System, comprising the Helical Infusion System Catheter and Morph Vascular Access Catheter, to deliver allogeneic, or "off-the-shelf," and autologous, or from the treated patient, mesenchymal (adult) stem cells (MSCs) via transendocardial injection.

7 Nov 2012

$Cryopraxis/CellPraxis initiates recruitment in ReACT Phase III trial for refractory angina$

Cryopraxis/CellPraxis initiates recruitment in ReACT Phase III trial for refractory angina

Cryopraxis/CellPraxis aims to start patient recruitment for its Phase III Refractory Angina Cell Therapy Brazilian arm clinical trial by the end of 2012 or early 2013.

6 Nov 2012

Receptor expression sheds light on nasal polyposis

The increased expression of a leukotriene receptor and a glucocorticoid receptor may contribute to the development of nasal polyposis, report researchers.

6 Nov 2012

Physical exercise may help preserve mobility in Parkinson’s patients

Aerobic and resistance exercise significantly improve fitness, gait speed, and muscle strength in patients with Parkinson’s disease, shows research published in the Archives of Neurology.

6 Nov 2012

Alnylam third quarter 2012 revenues decrease to $16.8 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter 2012, and company highlights.

6 Nov 2012

Sapacitabine tolerated, efficacious in elderly leukemia patients

The nucleoside analog sapacitabine appears to be “active and tolerable” in elderly patients with acute myeloid leukemia, say authors of a phase II study reported in the Lancet Oncology.

5 Nov 2012

PsiOxus receives UK government grant to initiate ColoAd1 Phase I/II trial for ovarian cancer

PsiOxus Therapeutics, Ltd., a development stage biotechnology company, today announced the award of a £1.7 million ($2.7 million) grant from the UK government-backed Biomedical Catalyst to initiate a Phase I/II clinical trial to assess the use of ColoAd1 in the treatment of platinum-resistant, recurrent ovarian cancer.

5 Nov 2012

Data from four Phase 2 trials of AMG 145 to be presented at AHA Scientific Sessions 2012

Amgen will present data from four Phase 2 trials of AMG 145, an investigational fully human monoclonal antibody directed against PCSK9, a protein that reduces the liver's ability to remove low density lipoprotein cholesterol, or "bad" cholesterol from the blood, at the upcoming American Heart Association Scientific Sessions 2012.

3 Nov 2012

Pfizer, Bristol-Myers Squibb announce data from ELIQUIS clinical trial on AF

Bristol-Myers Squibb Company and Pfizer Inc. today announced that a large number of data presentations sponsored by the companies on ELIQUIS (apixaban) and the treatment of atrial fibrillation will be presented at the American Heart Association 2012 Scientific Sessions, November 3-7, 2012, in Los Angeles, California.

3 Nov 2012

Lomitapide shows promise in treating homozygous familial hypercholesterolemia

An international effort led by researchers at the Perelman School of Medicine at the University of Pennsylvania has resulted in positive phase 3 clinical trial results for a new medicine to treat patients suffering from a rare and deadly cholesterol disorder.

3 Nov 2012

Autism interventions are supported by varying levels of evidence, reveals new RAND study

Interventions designed to improve core deficits in children with autism spectrum disorders are supported by varying levels of evidence, highlighting the need for well-designed studies to better evaluate the interventions, according to a new RAND Corporation study.

3 Nov 2012

Top-line results from Aerie Pharmaceuticals' AR-13324 Phase 2a study on glaucoma

Aerie Pharmaceuticals, a biotechnology company focused on the discovery and development of novel treatments for glaucoma, today announced positive top-line results from its Phase 2a study evaluating AR-13324 for the treatment of glaucoma.

3 Nov 2012

TD-1211 may relieve opioid-induced constipation

TD-1211 – an inhibitor of the mµ-opioid receptor – alleviates chronic noncancer-related constipation in patients receiving opioid therapy, without affecting pain relief, show the results of a parallel-group study.

2 Nov 2012

Virginia G. Piper, TESARO announce initiation of TSR-011 clinical trial for advanced cancer

TESARO, Inc. announced today that the first clinical trial of its proprietary Anaplastic Lymphoma Kinase (ALK) inhibitor, TSR-011, has commenced with the dosing of the first patient at the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen).

2 Nov 2012

Repeated surgeries may improve survival for patients with glioblastomas

People who undergo repeated surgeries to remove glioblastomas - the most aggressive and deadliest type of brain tumors - may survive longer than those who have just a one-time operation, new Johns Hopkins research suggests.

2 Nov 2012

Janssen, Vertex to evaluate TMC435 and VX-135 in Phase 2 HCV study

Janssen Pharmaceuticals, Inc. today announced that it has entered into a non-exclusive collaboration with Vertex Pharmaceuticals Incorporated to evaluate in a Phase 2 study the safety and efficacy of an all-oral regimen for the treatment of hepatitis C (HCV).

2 Nov 2012

TransTech Pharma to complete TTP054 Phase 2 trial on type 2 diabetes

TransTech Pharma, Inc., announced today that recruitment of patients for its recently initiated, multi-center Phase 2 clinical trial of TTP054 in type 2 diabetics, is exceeding expectations with initial top line results available in early 2013. The 90-day proof of concept study is being conducted in type 2 diabetics not well controlled with approved oral anti-diabetic agents.

2 Nov 2012

Efficacy News and Research

Positive results from Santarus and Pharming’s RUCONEST Phase III trial on HAE

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Lexicon announces data from LX4211 Phase 2b trial on type 2 diabetes

Positive results from BioCardia's Helical Infusion System Phase 1/2 trial on ischemic cardiomyopathy

Cryopraxis/CellPraxis initiates recruitment in ReACT Phase III trial for refractory angina

Receptor expression sheds light on nasal polyposis

Physical exercise may help preserve mobility in Parkinson’s patients

Alnylam third quarter 2012 revenues decrease to $16.8 million

Sapacitabine tolerated, efficacious in elderly leukemia patients

PsiOxus receives UK government grant to initiate ColoAd1 Phase I/II trial for ovarian cancer

Data from four Phase 2 trials of AMG 145 to be presented at AHA Scientific Sessions 2012

Pfizer, Bristol-Myers Squibb announce data from ELIQUIS clinical trial on AF

Lomitapide shows promise in treating homozygous familial hypercholesterolemia

Autism interventions are supported by varying levels of evidence, reveals new RAND study

Top-line results from Aerie Pharmaceuticals' AR-13324 Phase 2a study on glaucoma

TD-1211 may relieve opioid-induced constipation

Virginia G. Piper, TESARO announce initiation of TSR-011 clinical trial for advanced cancer

Repeated surgeries may improve survival for patients with glioblastomas

Janssen, Vertex to evaluate TMC435 and VX-135 in Phase 2 HCV study

TransTech Pharma to complete TTP054 Phase 2 trial on type 2 diabetes

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News